Management of patients with advanced HCC receiving atezolizumab/bevacizumab: Take care of cirrhosis!

Author:

Nault Jean-Charles123,Iavarone Massimo45ORCID

Affiliation:

1. Cordeliers Research Center, Sorbonne University, Inserm, Paris Cité University, “Functional Genomics of Solid Tumors” team, Ligue Nationale Contre le Cancer accredited team, Labex OncoImmunology, Paris, France

2. Liver Unit, Avicenne Hospital, APHP, Bobigny, France

3. University Sorbonne Paris Nord, Bobigny, France

4. Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy

5. CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference12 articles.

1. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

2. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma;Abou-Alfa;NEJM Evid,2022

3. Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment;Celsa;Hepatology

4. Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis;Allaire;Dig Liver Dis,2019

5. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis;Harrison;N Engl J Med,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3